Original Report: Laboratory Investigation
Rapamycin Prevents Early Steps of the Development of Diabetic Nephropathy in RatsYang Y. · Wang J. · Qin L. · Shou Z. · Zhao J. · Wang H. · Chen Y. · Chen J.
Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: Recent studies suggested the involvement of the Akt/mammalian target of rapamycin (mTOR) pathway in the pathogenesis of diabetic nephropathy. The effect of mTOR blockade by rapamycin in diabetic nephropathy was investigated, but in vivo study of rapamycin treatment in the course of early diabetes is still insufficient. This study was designed to determine the therapeutic effects of rapamycin on diabetic nephropathy at an early stage. Methods: Diabetes was induced in Sprague-Dawley rats with streptozotocin, and rapamycin (1 mg/kg) was administered by daily gavage for 4 weeks. Renal structural changes and some factors involved in the early pathogenesis of diabetic nephropathy were tested. The activation level of the Akt/mTOR pathway was also determined. Results: Rapamycin treatment reduced albuminuria, glomerular enlargement, glomerular basement membrane thickening, renal macrophage recruitment, and levels of renal mRNA expression of proliferating cell nuclear antigen, transforming growth factor-β1, vascular endothelial growth factor, and monocyte chemoattractant protein-1 without change in blood glucose level and blood pressure in experimental diabetic rats. In addition, treatment with rapamycin also down-regulated the enhanced levels of renal p-Akt, phospho-p70S6 kinase, and phospho-ribosomal S6 protein in diabetic rats. Conclusions: Rapamycin treatment can prevent the early renal structural changes of diabetes in experimental rats, and thus halt the early steps of the development of diabetic nephropathy. mTOR blockade might be beneficial for the treatment of diabetic nephropathy.
© 2007 S. Karger AG, Basel
- Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393–405.
- Young BA, Johnson RJ, Alpers CA, Eng E, Gordon K, Floege J, Couser WG: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935–944.
- Nyengaard JR, Rasch R: The impact of experimental diabetes mellitus in rats on glomerular capillary number and size. Diabetologia 1993;36:189–194.
- Van Det NF, Verhagen NAM, Tamsma JT, Berden JHM, Bruijn JA, Daha MR, Van Der Woude FJ: Regulation of glomerular epithelial cell production of fibronectin and transforming growth factor-β by high glucose, not by angiotensin II. Diabetes 1997;46:834–840.
- Rasch R, Norgaard JO: Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 1983;25:280–287.
- Gruden G, Setti G, Hayward A, Sugden D, Duggan S, Burt D, Buckingham RE, Gnudi L, Viberti G: Mechanical stretch induces monocyte chemoattractant activity via an NF-κB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005;16:688–696.
- Fingar DC, Salama S, Tsou C, Harlow E, Blenis J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002;16:1472–1487.
- Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, Fukatsu A, Yanagita M, Nakano T, Ishimoto Y, Kita T, Doi T, Arai H: Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005;68:552–561.
- Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000;103:253–262.
- Chen JK, Chen J, Neilson EG, Harris RC: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005;16:1384–1391.
- Wang W, Chan YH, Lee W, Chan L: Effect of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 2001;33:1036–1037.
Lock HSS, Robson MG: Non-immunosuppressive levels of rapamycin inhibit mesangial cell proliferation and extracellular matrix production (abstract). J Am Soc Nephrol 2004;15:SA-PO 908.
- Zhang D, Brodt P: Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974–982.
- Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006;17:1395–1404.
- Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, Bawab SEl: Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 2005;579:1249–1254.
- Sassy-Prigent G, Heudes D, Mandet C, Bélair MF, Michel O, Perdereau B, Bariéty J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000;49:466–475.
- Meyer TW, Rennke HG: Increased single-nephron protein excretion after renal ablation in nephrotic rats. Am J Physiol 1988;255:F1243–F1248.
- Marquez B, Zouvani I, Karagrigoriou A, et al: A simplified method for measuring the thickness of glomerular basement membranes. Ultrastruct Pathol 2003;27:409–416.
- Mahadevan P, Larkins RG, Fraser JR, Dunlop ME: Effect of prostaglandin E2 and hyaluronan on mesangial cell proliferation: a potential contribution to glomerular hypercellularity in diabetes. Diabetes 1996;45:44–50.
- Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB, El Nahas AM: Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997;12:43–50.
- Goruppi S, Bonventre JV, Kyriakis JM: Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002;21:5427–5436.
- Gorin Y, Kim NH, Feliers D, Bhandari B, Choudhory GG, Abboud HE: Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J 2001;15:1909–1920.
- Feliers D, Duraisamy S, Faulkner JL, Duch J, Lee AV, Abboud HE, Choudhury GG, Kasinath BS: Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int 2001;60:495–504.
- Chung J, Kuo CJ, Crabtree GR, Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kD S6 protein kinases. Cell 1992;69:1227–1236.
- Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M: Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004;23:4624–4635.
- Galkina E, Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006;17:368–377.
- Gruden G, Zonca S, Hayward A, Thomas S, Maestrini S, Gnudi L, Viberti GC: Mechanical stretch-induced fibronectin and transforming growth factor-β1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 2000;49:655–661.
- Utimura R, Fujihara CK, Mattar AL, Malheiros DMAC, Noronha IL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63:209–216.
- Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, Okada S, Wada J, Nagase R, Ogawa D, Shika Y, Makino H: Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005;16:3326–3338.
- Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004;15:S55–S57.
- De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993–1000.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.